Engineered Herpes Simplex Viruses for the Treatment of Malignant Peripheral Nerve Sheath Tumors
Abstract
The first year of our funding has been very productive and has led to new information regarding susceptibility of Malignant peripheral nerve sheath tumors (MPNST), which occur in patients with neurofibromatosis type-1, to oncolytic HSV (oHSVs). We have demonstrated that many of the MPNSTs that have tested are indeed sensitive to our oHSV, but that some are resistant (both murine and human). It is apparent from our data that ability to replicate in these tumor cells is related to additional factors besides simply status of HSV-1 receptors nectin-1 and nectin-2. We are examining further mechanisms that may be responsible for sensitivity and resistance in these lines which we hope to exploit in the future. We are currently testing 2 new hypotheses developed based upon the first year of data and are pursuing a surprising observation regarding the C134 and the M032 viruses and there ability to maintain late viral protein synthesis in the infected MPNST cells. This is an unanticipated finding that could have been discovered empirically these advances would not have been possible without these DOD funded studies.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2012
- Accession Number
- ADA580018
Entities
People
- James M. Markert
Organizations
- University of Alabama